FDA clears Zyn risk-reduction marketing

The U.S. Food and Drug Administration has issued modified-risk marketing orders for 20 Zyn nicotine pouch products owned by Philip Morris (PM). The decision allows these products to be marketed as less harmful than cigarettes, a designation that permits specific language about reduced health risks when adult smokers switch from cigarettes to Zyn.

Under the orders, the products may carry a claim that switching from cigarettes to Zyn lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis. This marks a significant regulatory step for nicotine pouches, enabling explicit communication about comparative disease risks for adult smokers.

The authorization applies to 20 distinct Zyn variants. These include Zyn Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint and Wintergreen, each offered in 3-milligram and 6-milligram nicotine strengths. Together, these flavors and strengths make up the set of products now allowed to carry the modified-risk claim.

The same 20 products had already been cleared for sale in January 2025, but that earlier authorization did not permit any marketing that described them as reducing disease risk. The new decision extends the regulatory status of these pouches by adding permission for reduced-risk messaging targeted at adult smokers.

FDA officials stated that the review of modified-risk products is intended to ensure adult users receive clear, science-based information about the relative harms of tobacco products. The agency framed the decision as providing adult smokers with evidence-based guidance on lower-risk alternatives to cigarettes within the tobacco category.

At the same time, the FDA emphasized that the decision does not mean Zyn is safe. The agency reiterated that there is no safe tobacco product and that adults who do not use tobacco products should not start. These caveats are intended to limit misinterpretation of the modified-risk designation as a blanket safety endorsement.

Philip Morris (PM) U.S. leadership described the decision as an important moment for more than 45 million legal-age nicotine consumers in the United States. The company highlighted that adults now have access to what it describes as accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to Zyn reduces the risk of certain smoking-related diseases such as heart disease and lung cancer.

Public health critics have expressed concern that flavored nicotine pouches, combined with social media promotion and the ability to use the products in workplaces, could normalize nicotine use among people who were not previously smokers. These critics caution that broader availability and marketing of flavored pouches may increase experimentation and uptake among populations that otherwise might not have used nicotine products.

The tension between enabling reduced-risk communication for current smokers and preventing initiation among non-users is central to the regulatory debate. The FDA’s orders attempt to balance these objectives by allowing specific risk-reduction claims for adult smokers, while underscoring that non-users should avoid tobacco products altogether.